Search hospitals > Nebraska > Omaha
Children's Hospital and Medical Center of Omaha
Claim this profileOmaha, Nebraska 68114
Global Leader in Uterine Tumors
Global Leader in T-Lymphoblastic Leukemia/Lymphoma
Conducts research for Cancer
Conducts research for Neuroblastoma
Conducts research for Lymphoma
197 reported clinical trials
7 medical researchers
Summary
Children's Hospital and Medical Center of Omaha is a medical facility located in Omaha, Nebraska. This center is recognized for care of Uterine Tumors, T-Lymphoblastic Leukemia/Lymphoma, Cancer, Neuroblastoma, Lymphoma and other specialties. Children's Hospital and Medical Center of Omaha is involved with conducting 197 clinical trials across 378 conditions. There are 7 research doctors associated with this hospital, such as Jill C. Beck, Minnie Abromowitch, Chittalsinh Raulji, MD, and Jeffrey Delaney, MD.Area of expertise
1Uterine Tumors
Global LeaderStage IV
Stage I
Stage II
2T-Lymphoblastic Leukemia/Lymphoma
Global LeaderStage II
NTRK1 positive
NTRK positive
Top PIs
Jill C. BeckChildren's Hospital and Medical Center of Omaha5 years of reported clinical research
Expert in Uterine Tumors
Expert in Cancer
54 reported clinical trials
110 drugs studied
Minnie AbromowitchChildren's Hospital and Medical Center of Omaha7 years of reported clinical research
Expert in Uterine Tumors
Expert in Cancer
41 reported clinical trials
86 drugs studied
Chittalsinh Raulji, MDUniversity of Nebraska Medical Center2 years of reported clinical research
Studies Cerebral Gliomas
Studies Brain Tumor
2 reported clinical trials
2 drugs studied
Jeffrey Delaney, MDChildren's Hospital & Medical Center3 years of reported clinical research
Studies Heart Disease
Studies Congenital Heart Defects
1 reported clinical trial
1 drug studied
Clinical Trials running at Children's Hospital and Medical Center of Omaha
Acute Lymphoblastic Leukemia
Brain Tumor
Acute Myeloid Leukemia
T-Lymphoblastic Leukemia/Lymphoma
Testicular cancer
Leukemia
Lymphoid Leukemia
Acute Leukemia
Uterine Tumors
Lymphoma
Levocarnitine
for Chemotherapy-Related Liver Protection in Leukemia and Lymphoma
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Recruiting2 awards Phase 3
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Blinatumomab + Dasatinib/Imatinib
for Acute Lymphoblastic Leukemia
This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-like) B-Cell acute lymphoblastic leukemia (B-ALL). Blinatumomab is a bispecific antibody that binds to two different proteins-one on the surface of cancer cells and one on the surface of cells in the immune system. An antibody is a protein made by the immune system to help fight infections and other harmful processes/cells/molecules. Blinatumomab may bind to the cancer cell and a T cell (which plays a key role in the immune system's fighting response) at the same time. Blinatumomab may strengthen the immune system's ability to fight cancer cells by activating the body's own immune cells to destroy the tumor. Dasatinib and imatinib are in a class of medications called tyrosine kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Giving blinatumomab and dasatinib or imatinib in combination with standard chemotherapy may work better in treating patients with Ph+ or Ph-like ABL-class B-ALL than dasatinib or imatinib with chemotherapy.
Recruiting2 awards Phase 35 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Children's Hospital and Medical Center of Omaha?
Children's Hospital and Medical Center of Omaha is a medical facility located in Omaha, Nebraska. This center is recognized for care of Uterine Tumors, T-Lymphoblastic Leukemia/Lymphoma, Cancer, Neuroblastoma, Lymphoma and other specialties. Children's Hospital and Medical Center of Omaha is involved with conducting 197 clinical trials across 378 conditions. There are 7 research doctors associated with this hospital, such as Jill C. Beck, Minnie Abromowitch, Chittalsinh Raulji, MD, and Jeffrey Delaney, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.